Preferred Label : Anti-PD-1 Antibody AI-025/Anti-CTLA-4 Antibody ONC-392 Combination Formulation AI-061;
NCIt synonyms : Monoclonal Antibodies Combination Formulation AI-061; ONC-392/AI-025; AI-025/ONC-392; Anti-PD-1 Antibody AI-025/Anti-CTLA-4 Antibody ONC-392 Combination AI-061; AI-025/Gotistobart Combination AI-061; Anti-PD-1 Antibody AI-025/Gotistobart Combination AI-061; Co-formulation AI-025/ONC-392;
NCIt definition : A 1:1 fixed dose combination formulation composed of the two monoclonal antibodies
AI-025, a monoclonal antibody directed against the negative immunoregulatory human
cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), and gotistobart,
a pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human
T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4;
CD152), with potential immune checkpoint inhibitory and antineoplastic activities.
Upon administration of anti-PD-1 antibody AI-025/anti-CTLA-4 antibody ONC-392 combination
formulation AI-061, AI-025 targets, binds to and inhibits PD-1 and ONC-392 targets,
binds to and inhibits CTLA-4. This inhibits the PD-1- and CTLA-4-mediated downregulation
of T-cell activation and proliferation. This restores immune function and activates
a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both
PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME)
and negatively regulate the activation and effector functions of T-cells. They play
key roles in the downregulation of the immune system and tumor evasion from host immunity.
Dual checkpoint blockade of PD-1 and CTLA-4 enhances T-cell activation and proliferation
more than the blockade of either immune checkpoint receptor alone. PD-1, a transmembrane
protein in the immunoglobulin superfamily (IgSF) expressed on T-cells, functions as
an immune checkpoint that negatively regulates T-cell activation and effector function
when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of
differentiation 274; CD274) or 2 (PD-L2; CD273); it plays an important role in tumor
evasion from host immunity. CTLA-4, an inhibitory receptor and member of the immunoglobulin
superfamily (IgSF), plays a key role in the downregulation of the immune system.;
Molecule name : AI-061; AI 061;
Origin ID : C200804;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
